{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-034701","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.793138+00:00","generated_at":"2026-06-04T09:41:12.271227+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lyra Therapeutics reports FY2023 net loss $62.7M; ENLIGHTEN I Phase 3 topline expected Q2 2024","bullets":["Net loss $62.7M in FY2023 ($15.1M Q4); R&D $48.0M, G&A $19.1M; cash $102.8M, runway into Q1 2025.","Topline results from ENLIGHTEN I Phase 3 trial of LYR-210 in CRS anticipated Q2 2024.","ENLIGHTEN II enrollment completion expected H2 2024; ENLIGHTEN I 52-week extension results Q4 2024.","BEACON Phase 2 of LYR-220 met safety endpoint; significant SNOT-22 (−16.8; p=0.007) and 3CS (−1.50; p=0.02) improvement vs sham at week 24."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-034701","json":"https://secwatch.observer/filing/0000950170-24-034701.json","markdown":"https://secwatch.observer/filing/0000950170-24-034701.md","text":"https://secwatch.observer/filing/0000950170-24-034701.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017024034701/0000950170-24-034701-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017024034701/lyra-20240321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:41:12.271227+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c533fdf291cb4da39934d2473239092c056f774","claim":"Lyra Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"announced its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1327273/000095017024034701/0000950170-24-034701-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}